Fibrate therapy in the management of diabetic dyslipidemia: there is no ACCORD to be found.

Current Atherosclerosis Reports
Peter P Toth

Abstract

Mixed dyslipidemia is a complex clinical entity that contributes significantly to the increased risk for cardiovascular morbidity and mortality that is observed in patients with type 2 diabetes mellitus. Insulin resistance is associated with reduced serum lipoprotein lipase activity, increased serum levels of very low-density lipoproteins and triglyceride, low serum high-density lipoproteins, and increased concentrations of small, dense low-density lipoproteins. Combinations of medications are frequently required in order to achieve guideline-specified goals for the various lipid fractions of diabetic patients. The fibric acid derivatives (fibrates) are effective agents for raising serum levels of high-density lipoproteins and decreasing levels of triglycerides. A number of trials have demonstrated that among patients with high triglycerides and low HDL, fibrates do beneficially impact cardiovascular morbidity in diabetic and nondiabetic individuals. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial suggests that the addition of fenofibrate to ongoing statin therapy in patients with type 2 diabetes mellitus offers limited benefit.

References

Jan 1, 1992·Annals of Epidemiology·W P CastelliD Levy
Jul 6, 2000·Circulation·UNKNOWN Bezafibrate Infarction Prevention (BIP) study
Dec 21, 2000·Current Atherosclerosis Reports·J C FruchartP Duriez
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Apr 30, 2003·Diabetes Care·Sander J RobinsUNKNOWN Veterans Affairs HDL Intervention Trial (VA-HIT)
Dec 25, 2004·Diabetes Care·UNKNOWN American Diabetes Association
May 14, 2005·Diabetes Research and Clinical Practice·Milagros J JacobsNathan D Wong
Jul 28, 2005·Diabetes·Bart Staels, Jean-Charles Fruchart
Nov 16, 2005·Journal of the American College of Cardiology·Jennifer G RobinsonHelmut Schrott
Dec 22, 2005·Current Medical Research and Opinion·Eric BruckertJohn Chapman
Apr 21, 2007·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Anette E BuykenGerd Assmann
Jul 20, 2007·JAMA : the Journal of the American Medical Association·Børge G NordestgaardAnne Tybjaerg-Hansen
Jul 20, 2007·JAMA : the Journal of the American Medical Association·Sandeep BansalPaul M Ridker
Mar 17, 2010·The New England Journal of Medicine·Henry N GinsbergRobert P Byington
Jul 1, 2007·Journal of Clinical Lipidology·Peter P Toth, Chris J Cadman

❮ Previous
Next ❯

Citations

Dec 2, 2010·Metabolic Syndrome and Related Disorders·Harold E BaysBarry Gumbiner
Jul 12, 2011·Current Opinion in Lipidology

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Current Treatment Options in Cardiovascular Medicine
Nadia Khoury, Anne Carol Goldberg
Seminars in Vascular Medicine
Markku Laakso
Lipids in Health and Disease
Krishnaswami Vijayaraghavan
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Amit Khera, Darren K McGuire
© 2021 Meta ULC. All rights reserved